Compare TAL Education Group American Depositary Shares (TAL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAL Education Group American Depositary Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? TAL Education Group American Depositary Shares trades at $12.44 (market cap $7.01B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: TAL Education Group American Depositary Shares is the larger of the two by market cap, and TAL Education Group American Depositary Shares is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TAL Education Group American Depositary Shares for 3 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TAL | TVTX | |
|---|---|---|
Market Cap | $7.01B | $4.88B |
Volume | 3,223,678 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $12.91 | $67.52 |
52-Week Low | $8.95 | $26.79 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $4.54B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAL Education Group trades at $12.64, down 0.63% with strong bullish technical signals from moving averages. The company demonstrates impressive fundamental strength with 28.43% net income margin and 23.72% ROE, supported by three consecutive earnings beats. Revenue growth accelerated from $2.25B in 2025 to $3.2B in 2026, while profitability surged from $85M to $907M net income. Analyst consensus shows 42.86% buy ratings with price targets suggesting 27.63% upside potential.
TAL presents a compelling investment case with strong earnings momentum and attractive valuation at 7.92 P/E. However, investors face risks from China's regulatory environment and the company's negative cash flow position of -$465.75M in 2025. The technical setup supports near-term upside with key resistance at $13 and support at $12, while institutional sentiment remains positive despite cash flow concerns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TAL Education Group American Depositary Shares
TAL Education Group provides smart learning solutions in China. Its offerings combine teaching content, technology, and learning services through various online and offline formats.
Read more on TAL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
